Head-To-Head Review: Microbot Medical (MBOT) vs. Mesoblast (MESO)

Microbot Medical (NASDAQ: MBOT) and Mesoblast (NASDAQ:MESO) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, risk, institutional ownership, earnings, valuation, dividends and analyst recommendations.

Profitability

This table compares Microbot Medical and Mesoblast’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Microbot Medical N/A -53.63% -49.61%
Mesoblast -188.83% -9.78% -8.03%



Analyst Ratings

This is a breakdown of recent ratings and target prices for Microbot Medical and Mesoblast, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Microbot Medical 0 0 1 0 3.00
Mesoblast 1 0 4 0 2.60

Microbot Medical currently has a consensus price target of $1.75, indicating a potential upside of 130.26%. Mesoblast has a consensus price target of $15.00, indicating a potential upside of 142.72%. Given Mesoblast’s higher probable upside, analysts plainly believe Mesoblast is more favorable than Microbot Medical.

Valuation and Earnings

This table compares Microbot Medical and Mesoblast’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Microbot Medical $120,000.00 266.76 -$7.58 million N/A N/A
Mesoblast $2.41 million 241.48 -$76.81 million ($0.97) -6.37

Microbot Medical has higher earnings, but lower revenue than Mesoblast.

Institutional and Insider Ownership

4.7% of Microbot Medical shares are owned by institutional investors. Comparatively, 2.9% of Mesoblast shares are owned by institutional investors. 31.8% of Microbot Medical shares are owned by company insiders. Comparatively, 18.8% of Mesoblast shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Volatility and Risk

Microbot Medical has a beta of -0.05, suggesting that its stock price is 105% less volatile than the S&P 500. Comparatively, Mesoblast has a beta of 1.95, suggesting that its stock price is 95% more volatile than the S&P 500.

Microbot Medical Company Profile

Microbot Medical Inc., a pre-clinical medical device company, researches, designs, and develops next generation micro-robotics assisted medical technologies targeting the minimally invasive surgery space. The company's product candidates include Self Cleaning Shunt for the treatment of hydrocephalus and normal pressure hydrocephalus; and TipCAT, a semi-disposable, flexible, and self-propelled endoscope for use in colonoscopy procedures, as well as ViRob, a revolutionary autonomous crawling micro-robot technology, which can be controlled remotely or within the body. Microbot Medical Inc. was founded in 2010 and is based in Yokneam, Israel.

Mesoblast Company Profile

Mesoblast Limited develops cell-based medicines. The company has leveraged its proprietary technology platform based on mesenchymal lineage adult stem cells to establish a portfolio of late-stage product candidates. Its allogeneic cell product candidates target advanced stages of diseases with high and unmet medical needs, including cardiovascular conditions, immunologic and inflammatory conditions, orthopedic disorders, and oncology and hematology conditions. The company's products under the Phase III clinical trials include MPC-150-IM for chronic and end-stage heart failure; MPC-06-ID for chronic low back pain; and MSC-100-IV for acute graft versus host disease in children. It is also developing MPC-300-IV that is in Phase II clinical trials for the treatment of biologic refractory rheumatoid arthritis, and diabetic kidney diseases and type 2 diabetes. The company has a collaboration agreement with JCR Pharmaceuticals Co., Ltd. It has operations in the United States, Australia, Singapore, and Switzerland. Mesoblast Limited was founded in 2004 and is headquartered in Melbourne, Australia.

Receive News & Ratings for Microbot Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Microbot Medical and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply